Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121875 · ClinicalTrials.gov registry record
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 1
- Enrollment target
NCT00121875: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT00121875 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121875 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Growth hormone treatment improves body fat distribution but also causes insulin resistance. Scientists have recently linked insulin resistance with special stores of fat in the muscles, which can be measured by magnetic resonance imaging (MRI). The researchers hypothesize that growth hormone will paradoxically reverse the linkage between muscle fat stores and insulin resistance. To assess this association and to investigate the cause(s), the researchers will measure muscle fat stores during growth hormone treatment. Other parameters linked to insulin resistance (glucose tolerance, blood markers, and body composition) will also be assessed. This study may lead to improved strategies for monitoring growth hormone therapy.
Interventions
- DRUG somatropin (rDNA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-12 |
Why NCT00121875 stopped before completion
NCT00121875 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which somatropin (rDNA) is the first listed.
NCT00121875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00121875 about?
NCT00121875 is a clinical study titled "Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature". Growth hormone treatment improves body fat distribution but also causes insulin resistance. Scientists have recently linked insulin resistance with special stores of fat in the muscles, which can be measured by magnetic resonance imaging (MRI). The researchers hypothesize that growth hormone will pa...
What is the current status of trial NCT00121875?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2005-06. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00121875?
The interventions under investigation include: somatropin (rDNA) (DRUG).
Who is sponsoring clinical trial NCT00121875?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia